Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2706 Target Snapshot

Receptor-type tyrosine-protein phosphatase beta · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
296Compounds
32Assays
0Approved Drugs
615.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Receptor-type tyrosine-protein phosphatase beta shows clinical signal disease relevance led by retinal vein occlusion. 2 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P23467. Start with retinal vein occlusion, then reuse UniProt P23467 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with retinal vein occlusion, then reuse UniProt P23467 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
retinal vein occlusion

Receptor-type tyrosine-protein phosphatase beta shows clinical signal disease relevance led by retinal vein occlusion. 2 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with retinal vein occlusion because it currently carries clinical signal support. Linked drugs include RAZUPROTAFIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Receptor-type tyrosine-protein phosphatase beta as ChEMBL target CHEMBL2706, mapped to UniProt P23467. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Receptor-type tyrosine-protein phosphatase beta
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2706
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P23467
Receptor-type tyrosine-protein phosphatase beta
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Receptor-type tyrosine-protein phosphatase beta is the right protein anchor across sources, using UniProt P23467 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why retinal vein occlusion is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameReceptor-type tyrosine-protein phosphatase beta
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP23467
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelReceptor-type tyrosine-protein phosphatase beta
UniProt AccessionP23467
Component TypeProtein
Sequence Length1997 aa

Receptor-type tyrosine-protein phosphatase beta

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Receptor-type tyrosine-protein phosphatase beta, mapped to UniProt P23467. Sequence length is 1997 aa.

Mapped IDP23467
Review nameReceptor-type tyrosine-protein phosphatase beta
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

Receptor-type tyrosine-protein phosphatase beta shows clinical signal disease relevance led by retinal vein occlusion. 2 more disease programs remain visible in the same review block.

Clinical signal Phase II
retinal vein occlusion
1 linked drug · 1 direct · 1 efficacy
Linked drugRAZUPROTAFIB
Clinical signal Phase I
diabetic retinopathy
1 linked drug · 1 direct · 1 efficacy
Linked drugRAZUPROTAFIB
Clinical signal Phase I
glaucoma
1 linked drug · 1 direct · 1 efficacy
Linked drugRAZUPROTAFIB
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with retinal vein occlusion because it currently carries clinical signal support. Linked drugs include RAZUPROTAFIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseretinal vein occlusion
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

1
Phase II
Assay Mix

Activity Type Distribution

IC50599.0
KI16.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3928885 11.0 IC50 0.01 Preclinical
CHEMBL3935358 10.1 IC50 0.08 Preclinical
CHEMBL3948990 10.1 IC50 0.08 Preclinical
CHEMBL3963181 10.05 IC50 0.09 Preclinical
CHEMBL3907615 10.0 IC50 0.1 Preclinical
CHEMBL3962687 10.0 IC50 0.1 Preclinical
CHEMBL3967271 10.0 IC50 0.1 Preclinical
CHEMBL3945835 9.85 IC50 0.14 Preclinical
CHEMBL3921571 9.8 IC50 0.157 Preclinical
CHEMBL3891215 9.79 IC50 0.162 Preclinical
Distribution

pChEMBL Value Distribution

15
5.0
14
5.5
39
6.0
69
6.5
95
7.0
44
7.5
31
8.0
45
8.5
50
9.0
76
9.5
pChEMBL
Assay Landscape

Assay Landscape

35
Total Assays
190
Tested Compounds
2
Assay Types
Binding — 34 assays, 190 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 29 186 7.9
cell-based format 4 2 4.4
assay format 1 2 4.5
ADME — 1 assays, 1 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 1 4.9

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine